• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的T细胞:通过感染、疫苗接种以及针对未来变体

T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants.

作者信息

Nguyen Thi H O, Cohen Carolyn A, Rowntree Louise C, Bull Maireid B, Hachim Asmaa, Kedzierska Katherine, Valkenburg Sophie A

机构信息

Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.

HKU-Pasteur Research Pole, Li Ka Shing Faculty of Medicine, School of Public Health, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.

出版信息

Front Med (Lausanne). 2021 Dec 24;8:793102. doi: 10.3389/fmed.2021.793102. eCollection 2021.

DOI:10.3389/fmed.2021.793102
PMID:35004764
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8739267/
Abstract

T cell responses are a key cornerstone to viral immunity to drive high-quality antibody responses, establishing memory for recall and for viral clearance. Inefficient recruitment of T cell responses plays a role in the development of severe COVID-19 and is also represented by reduced cellular responses in men, children, and diversity compared with other epitope-specific subsets and available T cell receptor diversity. SARS-CoV-2-specific T cell responses are elicited by multiple vaccine formats and augmented by prior infection for hybrid immunity. Epitope conservation is relatively well-maintained leading to T cell crossreactivity for variants of concern that have diminished serological responses.

摘要

T细胞反应是病毒免疫的关键基石,可驱动高质量的抗体反应,建立用于回忆和病毒清除的记忆。T细胞反应募集效率低下在重症COVID-19的发展中起作用,并且在男性、儿童中以及与其他表位特异性亚群和可用的T细胞受体多样性相比的多样性方面,细胞反应减少也体现了这一点。多种疫苗形式可引发针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的T细胞反应,既往感染可增强T细胞反应以产生混合免疫。表位保守性相对良好地得以维持,导致对血清学反应减弱的关注变异株产生T细胞交叉反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b97a/8739267/d1cadf2a34e4/fmed-08-793102-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b97a/8739267/d1cadf2a34e4/fmed-08-793102-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b97a/8739267/d1cadf2a34e4/fmed-08-793102-g0001.jpg

相似文献

1
T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants.靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的T细胞:通过感染、疫苗接种以及针对未来变体
Front Med (Lausanne). 2021 Dec 24;8:793102. doi: 10.3389/fmed.2021.793102. eCollection 2021.
2
Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.杂合免疫改变了 SARS-CoV-2 mRNA 疫苗诱导免疫的 Fc 效应子质量。
mBio. 2022 Oct 26;13(5):e0164722. doi: 10.1128/mbio.01647-22. Epub 2022 Aug 24.
3
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.新型冠状病毒刺突蛋白受体结合域线性表位在 COVID-19 mRNA 疫苗接种者中的高分辨率线性表位作图。
Microbiol Spectr. 2021 Dec 22;9(3):e0096521. doi: 10.1128/Spectrum.00965-21. Epub 2021 Nov 10.
4
The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants.突破性感染后回忆性免疫的程度和时间由 SARS-CoV-2 变体决定。
Immunity. 2022 Jul 12;55(7):1316-1326.e4. doi: 10.1016/j.immuni.2022.05.018. Epub 2022 May 27.
5
Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.两剂蛋白亚单位疫苗 MVC-COV1901 初免后加强接种多剂 mRNA 疫苗可增强针对新型 SARS-CoV-2 变异株的体液和细胞免疫应答。
Microbiol Spectr. 2022 Oct 26;10(5):e0060922. doi: 10.1128/spectrum.00609-22. Epub 2022 Aug 25.
6
Cross-reactive humoral and CD4 T cell responses to Mu and Gamma SARS-CoV-2 variants in a Colombian population.哥伦比亚人群中对 Mu 和 Gamma SARS-CoV-2 变体的交叉反应性体液和 CD4 T 细胞应答。
Front Immunol. 2023 Jul 27;14:1241038. doi: 10.3389/fimmu.2023.1241038. eCollection 2023.
7
Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants.新冠疫苗诱导的针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体的刺突蛋白特异性免疫的持久性
Biomedicines. 2022 Apr 26;10(5):996. doi: 10.3390/biomedicines10050996.
8
Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.奥密克戎 BA.1 特异性 T 细胞应答在香港接种科兴或辉瑞疫苗的成年人中的观察性队列研究。
Lancet Microbe. 2023 Jun;4(6):e418-e430. doi: 10.1016/S2666-5247(23)00006-X. Epub 2023 Apr 20.
9
Dynamics of Antibody and T Cell Immunity against SARS-CoV-2 Variants of Concern and the Impact of Booster Vaccinations in Previously Infected and Infection-Naïve Individuals.针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)关注变异株的抗体和T细胞免疫动力学以及加强疫苗接种对既往感染者和未感染者的影响
Vaccines (Basel). 2022 Dec 13;10(12):2132. doi: 10.3390/vaccines10122132.
10
SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.COVID-19 康复者感染后 1 年的 SARS-CoV-2 特异性抗体和 T 细胞反应:一项纵向队列研究。
Lancet Microbe. 2022 May;3(5):e348-e356. doi: 10.1016/S2666-5247(22)00036-2. Epub 2022 Mar 23.

引用本文的文献

1
Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses Between Infection and Vaccination: Challenges for Epidemiological Research.区分严重急性呼吸综合征冠状病毒2感染与疫苗接种后的抗体反应:流行病学研究面临的挑战
J Infect Dis. 2025 Jul 30;232(1):9-13. doi: 10.1093/infdis/jiaf295.
2
Investigation of Long-Term CD4+ T Cell Receptor Repertoire Changes Following SARS-CoV-2 Infection in Patients with Different Severities of Disease.不同疾病严重程度的新冠病毒感染患者感染后长期CD4+ T细胞受体库变化的研究
Diagnostics (Basel). 2024 Oct 19;14(20):2330. doi: 10.3390/diagnostics14202330.
3
Clonal structure and the specificity of vaccine-induced T cell response to SARS-CoV-2 Spike protein.

本文引用的文献

1
Mix and match COVID-19 vaccines: potential benefit and perspective from India.混合使用新冠疫苗:来自印度的潜在益处及前景
Postgrad Med J. 2022 Mar 1;98(e2):e99-e101. doi: 10.1136/postgradmedj-2021-140648.
2
Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time.新型冠状病毒2(SARS-CoV-2)感染随时间推移对疫苗诱导的免疫反应的影响。
Clin Transl Immunology. 2022 Apr 18;11(4):e1388. doi: 10.1002/cti2.1388. eCollection 2022.
3
SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans.
新冠病毒刺突蛋白疫苗诱导的 T 细胞反应的克隆结构和特异性。
Front Immunol. 2024 Apr 2;15:1369436. doi: 10.3389/fimmu.2024.1369436. eCollection 2024.
4
Flublok Quadrivalent Vaccine Adjuvanted with R-DOTAP Elicits a Robust and Multifunctional CD4 T Cell Response That Is of Greater Magnitude and Functional Diversity Than Conventional Adjuvant Systems.与R-DOTAP佐剂联合的四价流感病毒裂解疫苗引发强大且多功能的CD4 T细胞应答,其强度和功能多样性均高于传统佐剂系统。
Vaccines (Basel). 2024 Mar 7;12(3):281. doi: 10.3390/vaccines12030281.
5
Comparing population-level humoral and cellular immunity to SARS-Cov-2 in Bangalore, India.比较印度班加罗尔地区人群对 SARS-CoV-2 的体液免疫和细胞免疫。
Sci Rep. 2024 Mar 8;14(1):5758. doi: 10.1038/s41598-024-54922-z.
6
Contribution of infection and vaccination to population-level seroprevalence through two COVID waves in Tamil Nadu, India.通过印度泰米尔纳德邦的两波 COVID 疫情,感染和疫苗接种对人群血清阳性率的贡献。
Sci Rep. 2024 Jan 24;14(1):2091. doi: 10.1038/s41598-023-50338-3.
7
Contribution of SARS-CoV-2 infection preceding COVID-19 mRNA vaccination to generation of cellular and humoral immune responses in children.SARS-CoV-2 感染对儿童 COVID-19 mRNA 疫苗接种后细胞和体液免疫应答的贡献。
Front Immunol. 2023 Dec 20;14:1327875. doi: 10.3389/fimmu.2023.1327875. eCollection 2023.
8
Convalescent Adaptive Immunity Is Highly Heterogenous after SARS-CoV-2 Infection.SARS-CoV-2感染后恢复期的适应性免疫高度异质性。
J Clin Med. 2023 Nov 16;12(22):7136. doi: 10.3390/jcm12227136.
9
COVID-19 vaccination exacerbates ex vivo IL-6 release from isolated PBMCs.COVID-19 疫苗接种可增强从分离的 PBMCs 体外释放的 IL-6。
Sci Rep. 2023 Jun 12;13(1):9496. doi: 10.1038/s41598-023-35731-2.
10
Architecture of the SARS-CoV-2-specific T cell repertoire.SARS-CoV-2 特异性 T 细胞库的结构。
Front Immunol. 2023 Mar 20;14:1070077. doi: 10.3389/fimmu.2023.1070077. eCollection 2023.
SARS-CoV-2 mRNA 疫苗可在人体内引发强烈且持久的滤泡辅助性 T 细胞反应。
Cell. 2022 Feb 17;185(4):603-613.e15. doi: 10.1016/j.cell.2021.12.026. Epub 2021 Dec 23.
4
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong.比较香港科兴和国药新冠疫苗的免疫原性。
Respirology. 2022 Apr;27(4):301-310. doi: 10.1111/resp.14191. Epub 2021 Nov 24.
5
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2.预先存在的聚合酶特异性 T 细胞在 SARS-CoV-2 无血清学阴性中扩增。
Nature. 2022 Jan;601(7891):110-117. doi: 10.1038/s41586-021-04186-8. Epub 2021 Nov 10.
6
Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2.SARS-CoV-2 小鼠模型中病毒清除和保护的适应性免疫决定因素。
Sci Immunol. 2021 Oct 15;6(64):eabl4509. doi: 10.1126/sciimmunol.abl4509. Epub 2021 Sep 2.
7
The impact of prioritisation and dosing intervals on the effects of COVID-19 vaccination in Europe: an agent-based cohort model.在欧洲,优先排序和给药间隔对 COVID-19 疫苗接种效果的影响:基于代理的队列模型。
Sci Rep. 2021 Sep 22;11(1):18812. doi: 10.1038/s41598-021-98216-0.
8
Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells.低剂量 mRNA-1273 COVID-19 疫苗可产生由交叉反应性 T 细胞增强的持久记忆。
Science. 2021 Oct 22;374(6566):eabj9853. doi: 10.1126/science.abj9853.
9
Cross-reactive CD4 T cells enhance SARS-CoV-2 immune responses upon infection and vaccination.交叉反应性 CD4 T 细胞增强了感染和接种 SARS-CoV-2 后的免疫反应。
Science. 2021 Oct 8;374(6564):eabh1823. doi: 10.1126/science.abh1823.
10
Antibody landscapes of SARS-CoV-2 can reveal novel vaccine and diagnostic targets.SARS-CoV-2 的抗体景观可以揭示新的疫苗和诊断靶点。
Curr Opin Virol. 2021 Oct;50:139-146. doi: 10.1016/j.coviro.2021.08.006. Epub 2021 Aug 20.